• Home
  • 2.0 LPBI Executive Summary
  • 1.0 LPBI Executive Summary
  • Journal PharmaceuticalIntelligence.com
  • Portfolio of IP Assets
  • Knowledge PORTALS System (KPS)
  • 1.0 LPBI – 2012-2020 VISTA
  • LPBI Group’s History
  • 2.0 LPBI – 2021-2025 VISION
  • BioMed e-Series
  • Press Coverage
  • Investor Relations
  • Our TEAM
  • Founder
  • Funding, Deals & Partnerships
  • 1.0 LPBI Group News
  • 1.0 LPBI CALENDAR
  • 2.0 LPBI Group News
  • Testimonials about LPBI
  • DrugDiscovery @LPBI Group
  • Medical 3D Printing
  • e-VOICES Podcasting
  • LPBI Newsletters
  • Customer Surveys
  • Health Care INVESTOR’s Corner ($)
  • 2021 Summer Internship Portal
  • 2021-2022 Medical Text Analysis (NLP)
  • Artificial Intelligence: Genomics & Cancer
  • SOP Web STAT
  • Blockchain Transactions Network Ecosystem
  • Contact Us
  • 1.0 LPBI Brochure
  • 2.0 LPBI Brochure
  • 2.0 LPBI – Calendar of Zooms
  • Coronavirus, SARS-CoV-2 Portal
  • LPBI India
  • Synthetic Biology in Drug Discovery
  • Certificate One Year
  • NFT: Redefined Format of IP Assets

Leaders in Pharmaceutical Business Intelligence (LPBI) Group

Funding, Deals & Partnerships: BIOLOGICS & MEDICAL DEVICES; BioMed e-Series; Medicine and Life Sciences Scientific Journal – http://PharmaceuticalIntelligence.com

Feeds:
Posts
Comments

Diabetes – A Combination Drug Therapy to induce Insulin Production by Pancreatic Beta Cells (PPAR-gamma, Leptin, ..)

Part I

Articles by LPBI Group’s Team Member

Adipocyte Derived Stroma Cells: Their Usage in Regenerative Medicine and Reprogramming into Pancreatic Beta-Like Cells

Curator: Evelina Cohn, PhD

Fat Cells Reprogrammed to Make Insulin

Curator: Larry H. Bernstein, MD, FCAP

 

Part II

Diabetes: All Drugs in Development

Curator: Stephen J Williams, PhD

 

 

Table 1. Drugs in Development1–3
Generic/Code Name Manufacturer Indication Phase
DPP-4 Inhibitors
Alogliptin/SYR-322 Takeda Type 2 diabetes NDA submitted
AMG 222/ALS2- 0426 Amgen/Servier Type 2 diabetes 2
Dutogliptin/PHX1149 Phenomix/Forest Laboratories Type 2 diabetes 3
KRP-204/N-5984 Kyorin Type 2 diabetes 2
KRP-104 Kyorin/ActivX Biosciences Type 2 diabetes 2
Linagliptin/BI-1356 Boehringer Ingelheim Type 2 diabetes 3
Melogliptin/GRC 8200 Glenmark Pharmaceuticals Type 2 diabetes 2
MP-513 Mitsubishi Tanabe Pharma Type 2 diabetes 2
PF 734200 Pfizer Type 2 diabetes 2
R1579 Roche/Chugai Type 2 diabetes 2
Saxagliptin/BMS-477118 Bristol-Myers Squibb/AstraZeneca Type 2 diabetes NDA submitted
SYR 472 Takeda Type 2 diabetes 2
TA-6666 Mitsubishi Tanabe Type 2 diabetes 2
Vildagliptin Novartis Type 2 diabetes NDA submitted
GLP-1 Analogs
Albiglutide/GSK716155 GSK Type 2 diabetes 2
AVE0010/ZP-10 Sanofi-Aventis Type 2 diabetes 3
CJC-1134-PC/PC-DAC: Exendin-4 ConjuChem Type 2 diabetes 2
Exenatide LAR Amylin/Alkermes/Lilly Type 2 diabetes 3
Liraglutide/NN2211 Novo Nordisk Type 2 diabetes NDA submitted
LY 2189265 Lilly Type 2 diabetes 3
NN9535 Novo Nordisk Type 2 diabetes 2
Taspoglutide/R1583/BIM-51077 Roche/Ipsen Type 2 diabetes 3
Biguanides
Metformin gum/buccal Generex/Fertin Pharma Type 2 diabetes 2
Thiazolidinediones/PPAR-γ Agonists
Balaglitazone/DRF-2593 Dr. Reddy’s Laboratories/Rheoscience Type 2 diabetes 3
Mitoglitazone/MDSC 0160 Metabolic Solutions Development Type 2 diabetes 2
Netoglitazone/MCC-55 Mitsubishi Tanabe/Perlegen Type 2 diabetes 2
Rivoglitazone/CS-011 Daiichi-Sankyo Type 2 diabetes 3
Other PPAR Agonists
Aleglitazar/R1439 Roche Type 2 diabetes 2
Indeglitazar Pexxikon/Wyeth Type 2 diabetes 2
INT 131/AMG131 Amgen/InteKrin Therapeutics Type 2 diabetes 2
MBX 2044 Metabolex/Ortho-McNeil Type 2 diabetes 2
Metaglidasen/MBX 102/JNJ-39659100 Metabolex/Ortho-McNeil Type 2 diabetes 2
ONO-5129 Ono Type 2 diabetes 2
PLX204/PPM-204 Plexxikon/Wyeth Type 2 diabetes 2
Selective Sodium Glucose Cotransporter Inhibitors
ASP1941 Astellas Type 2 diabetes 2
AVE2268 Sanofi-Aventis Type 2 diabetes 2
BI 10773 Boehringer Ingelheim Type 2 diabetes 2
Dapagliflozin/BMS512148 AstraZeneca/Bristol-Myers Squibb Type 2 diabetes 3
KGT-1681 GSK/Kissei Type 2 diabetes 2
Remogliflozin/189075 GSK/Kissei Type 2 diabetes 2
TA-7284 Mitsubishi Tanabe/Ortho McNeil Type 2 diabetes 2
YM543 Astellas Type 2 diabetes 2
Glinides
Mitiglinide Elixir Pharmaceuticals Type 2 diabetes 3
Insulins
Inhaled Technosphere insulin Mannkind Type 1 and type 2 diabetes 3
Insulin intranasal Bentley Type 1 and type 2 diabetes 2
Insulin intranasal MDRNA Type 2 diabetes 2
Oral HDV insulin Diasome Type 2 diabetes 2
Oral insulin spray Generex Type 1 and type 2 diabetes 3
NN1250 insulin analog for
injection		 Novo Nordisk Type 1 and type 2 diabetes 2
NN5401 insulin analog for
injection		 Novo Nordisk Type 1 and type 2 diabetes 2
Rapid-acting insulin for injection Biodel Type 1 and type 2 diabetes 3
Recombinant human hyaluroindase (rHuPH20)/insulin co-formulation for injection Halozyme Therapeutics Type 1 diabetes 2
Other Drugs in Development
Generic/Code Name Manufacturer Mechanism Indication
AJD101 Daiichi Sankyo Activates insulin signaling pathway Type 2 diabetes
AKP- 020 Akesis Vanadium compound Type 2 diabetes
AMG-108 Amgen Interleukin-1 inhibitor Type 2 diabetes
AZD6370 AstraZeneca Glucokinase activator Type 2 diabetes
Bromocriptine VeroScience Dopamine D2 receptor
agonist		 Type 2 diabetes
Canakinumab/ACZ885 Novartis Anti-interleukin-1 beta antibody Type 2 diabetes
Colestimide Mitsubishi-Tanabe Unknown Type 2 diabetes
Bezafibrate + diflunisal/ CRx-401 CombinatoRx Unknown Type 2 diabetes
DIO-902/2S,4R ketoconazole DiObex Cortisol synthesis inhibitor Type 2 diabetes
DM-71/bethanechol and N-acetyl cysteine Diamedica Unknown Type 2 diabetes
DM-83/combination of two generic compounds Diamedica Unknown Type 2 diabetes
E1 INT Transition Therapeutics Islet regeneration factor Type 1 and type 2 diabetes
Eprodisate/NC-503 Bellus Health Serum amyloid A protein inhibitor ?
Ex vivo cultured adult human mesenchymal stem cells Osiris Mesenchymal stem cell
therapy		 Type 1 diabetes
HE3286 Hollis-Eden Insulin sensitizer (NF-kappaB pathway/TLR4 receptor) Type 2 diabetes
INCB 13739 Incyte 11-beta hydroxysteroid dehydrogenase inhibitor Type 2 diabetes
INCB 19602 Incyte GPR109A receptor agonist / HM74a agonist Type 2 diabetes
INGAP peptide Kinexum Islet neogenesis associated protein Type 1 and type 2 diabetes
ISIS 113715 Isis PTP1B Type 2 diabetes
MB 07803 Metabasis/Daiichi
Sankyo		 Fructose-1,6-bisphosphatase inhibitor Type 2 diabetes
MK 0893 Merck Unknown Type 2 diabetes
MK 0941 Merck Unknown Type 2 diabetes
Otelixizumab/TRX4 GSK, Tolerx Anti-CD3 MAb Type 1 diabetes
rhGAD65/recombinant human glutamic acid decarboxylase Diamyd Therapeutics Vaccine/induces immunmotolerization Type 1 diabetes
Succinobucol/AGI 1067 AtheroGenics Antioxidant/vascular cell adhesion molecule-1 Type 2 diabetes
Tagatose Spherix Attenuates intestinal glucose absorption Type 2 diabetes
Teplizumab/MGA031/ hOKT3gamma1(Ala-Ala) Lilly/MacroGenics Anti-CD3 MAb Type 1 diabetes
TT-223 Lilly/Transition Therapeutics Gastrin analog Type 1 and type 2 diabetes

 

Like this:

Like Loading...

  • Follow Blog via Email

    Enter your email address to follow this blog and receive notifications of new posts by email.

    Join 1,979 other subscribers

  • Recent Posts

    • Omecamtiv mecarbil – A study examined efficacy and tolerability in Heart Failure patients with SBP ≤100 mmHg enrolled in GALACTIC-HF May 23, 2022
    • Sperm epigenetic clock and pregnancy outcomes May 14, 2022
    • Lessons on the Frontier of Gene & Cell Therapy – The Disruptive Dozen 12 #GCT Breakthroughs that are revolutionizing Healthcare May 9, 2022
    • Relevance of Twitter.com forthcoming Payment System for Scientific Content Promotion and Monetization May 9, 2022
    • Tweets at #WMIF2022 by @pharma_BI & @AVIVA1950 and all Retweets of these Tweets – 2022 World Medical Innovation Forum, GENE & CELL THERAPY • MAY 2–4, 2022 • BOSTON May 7, 2022
    • Data Science: Step by Step – A Resource for LPBI Group’s One-Year Internship in IT, IS, DS May 7, 2022
    • 2022 World Medical Innovation Forum, GENE & CELL THERAPY • MAY 2–4, 2022 • BOSTON • IN-PERSON May 1, 2022
    • We Celebrate TEN Years of Excellence, LPBI Group: 4/2012 – 4/2022 April 25, 2022
    • The durability of T cells versus the triggered of high levels of antibodies: Rationale for the development of T cells focused vaccines   April 22, 2022
    • The Framingham Study: Across 6 Decades, Cardiovascular Disease Among Middle-Aged Adults – mean life expectancy increased and the RLR of ASCVD decreased. Effective primary prevention efforts and better screening increased. April 22, 2022

  • Archives

  • Categories

  • Meta

    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org

    • 1 2012pharmaceutical
    • 1 Amandeep Kaur
    • 1 Aashir Awan, Phd
    • 1 Abhisar Anand
    • 1 Adina Hazan
    • 1 Alan F. Kaul, PharmD., MS, MBA, FCCP
    • 1 alexcrystal6
    • 1 anamikasarkar
    • 1 apreconasia
    • 1 aviralvatsa
    • 1 David Orchard-Webb, PhD
    • 1 danutdaagmailcom
    • 1 Demet Sag, Ph.D., CRA, GCP
    • 1 Dror Nir
    • 1 dsmolyar
    • 1 Ethan Coomber
    • 1 evelinacohn
    • 1 Gail S Thornton
    • 1 Irina Robu
    • 1 jayzmit48
    • 1 jdpmd
    • 1 jshertok
    • 1 kellyperlman
    • 1 Ed Kislauskis
    • 1 larryhbern
    • 1 Madison Davis
    • 1 marzankhan
    • 1 megbaker58
    • 1 ofermar2020
    • 1 Dr. Pati
    • 1 pkandala
    • 1 Rosalind Codrington, PhD
    • 1 ritusaxena
    • 1 Rick Mandahl
    • 1 sjwilliamspa
    • 1 Srinivas Sriram
    • 1 stuartlpbi
    • 1 Dr. Sudipta Saha
    • 1 tildabarliya
    • 1 vaishnavee24
    • 1 zraviv06
    • 1 zs22

Powered by WordPress.com.

WPThemes.


%d bloggers like this: